- Home
- TDF vs BWAY Comparison
TDF vs BWAY Comparison
Compare TDF & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDF
- BWAY
- Stock Information
- Founded
- TDF 1994
- BWAY 2003
- Country
- TDF Singapore
- BWAY Israel
- Employees
- TDF N/A
- BWAY N/A
- Industry
- TDF Finance/Investors Services
- BWAY Medical/Dental Instruments
- Sector
- TDF Finance
- BWAY Health Care
- Exchange
- TDF Nasdaq
- BWAY Nasdaq
- Market Cap
- TDF 244.7M
- BWAY 201.1M
- IPO Year
- TDF N/A
- BWAY 2019
- Fundamental
- Price
- TDF $9.47
- BWAY $10.20
- Analyst Decision
- TDF
- BWAY Strong Buy
- Analyst Count
- TDF 0
- BWAY 2
- Target Price
- TDF N/A
- BWAY $14.25
- AVG Volume (30 Days)
- TDF 79.2K
- BWAY 33.6K
- Earning Date
- TDF 01-01-0001
- BWAY 05-13-2025
- Dividend Yield
- TDF N/A
- BWAY N/A
- EPS Growth
- TDF N/A
- BWAY N/A
- EPS
- TDF N/A
- BWAY 0.08
- Revenue
- TDF N/A
- BWAY $43,457,000.00
- Revenue This Year
- TDF N/A
- BWAY $351.53
- Revenue Next Year
- TDF N/A
- BWAY $21.84
- P/E Ratio
- TDF N/A
- BWAY $51.42
- Revenue Growth
- TDF N/A
- BWAY 26.86
- 52 Week Low
- TDF $7.15
- BWAY $5.67
- 52 Week High
- TDF $10.62
- BWAY $11.79
- Technical
- Relative Strength Index (RSI)
- TDF 48.70
- BWAY 56.24
- Support Level
- TDF $9.48
- BWAY $10.15
- Resistance Level
- TDF $9.70
- BWAY $11.06
- Average True Range (ATR)
- TDF 0.13
- BWAY 0.53
- MACD
- TDF -0.02
- BWAY 0.04
- Stochastic Oscillator
- TDF 6.67
- BWAY 64.90
About TDF Templeton Dragon Fund Inc.
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.